WuXi STA and Antengene partner under MAH scheme

By Flora Southey contact

- Last updated on GMT

(Image: Getty/JavierHuras)
(Image: Getty/JavierHuras)

Related tags: China, Asia pacific, Wuxi

Antengene has selected CMO WuXi STA to develop and manufacture its mTOR inhibitor product ATG-008 for Chinese and Asia-Pacific markets.

According to the terms, Chinese contract development and manufacturing organisation (CDMO) STA Pharmaceutical (WuXi STA) – a subsidiary of WuXi AppTec – will provide process R&D and manufacturing services for Antengene’s oncology drugs.

The collaboration will focus on Antengene’s Phase II/III mTOR inhibitor candidate ATG-008, designed for the treatment of hepatitis B virus positive advanced hepatocellular carcinoma (HCC) patients, and extend to commercial-stage assets.

Antengene’s pipeline focuses on relapsed/refractory multiple myeloma, lymphomas and solid tumours, as well as colorectal and prostate cancers. Early-phase ATG-527 is being explored for anti-viral indications such as influenza, RSV (respiratory syncytial virus infection), and EB (Epstein Barr) viral-related diseases.

The partnership marks the first time the companies have collaborated, and will target Chinese and Asia-Pacific regions, a WuXi STA spokesperson told us.

According to Antengene CEO Jay Mei, “WuXi STA’s end-to-end CMC [chemistry, manufacturing, and controls] platform enables us to focus on our research and development, and to move our drug candidates from clinical-stage to commercialisation more efficiently. We look forward to a much broader collaboration in the near future.”

The agreement follows on from China’s 2016 Marketing Authorisation Holder (MAH) pilot programme​, which enables good manufacturing practice (GMP)-compliant third party manufacturers, in some provinces, to make pharmaceutical drug products for customers.

Last month​, China approved its first CMO-made new drug since the implementation of the MAH scheme – Ascletis’ viral hepatitis C treatment Ganovo – which had been made by WuXi STA.

Related news

Show more

Related products

Innovations in OSD

Innovations in OSD

Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars